Myeloid Cell Markers

Introduction

Myeloid cells, originating from myeloid progenitors in the bone marrow, constitute a diverse group of immune cells including monocytes, macrophages, dendritic cells (DCs), and granulocytes (neutrophils, eosinophils, and basophils). These cells are vital for the innate immune response, professional antigen presentation, and tissue remodeling. Their functional states are defined by specific surface proteins known as cluster of differentiation (CD) markers. Creative Biolabs provides high-specificity antibodies and cutting-edge liposome technologies, empowering researchers to pioneer precision therapies for cancer and inflammatory disorders.

Fig.1 Myeloid Cells Markers and antibody-conjugated liposomes (Creative Biolabs AI)

Key Classification of Myeloid Cells Markers

Cell Type	Primary Markers	Biological Significance & Role
Pan-Myeloid	CD11b, CD33	CD11b (integrin αM) is essential for leukocyte adhesion; CD33 is a hallmark of the myeloid lineage.
Monocytes	CD14, CD16	CD14 is a co-receptor for LPS; CD16 identifies "non-classical" patrolling monocytes.
Macrophages	CD68, CD163, CD206	CD68 is a pan-macrophage marker; CD163 and CD206 identify M2-polarized (anti-inflammatory) cells.
Dendritic Cells	CD11c, HLA-DR, CD80/86	CD11c is the primary marker for conventional DCs; CD80/86 are co-stimulatory molecules for T cell activation.
Neutrophils	CD15, CD66b, Ly6G	Crucial for identifying the most abundant granulocyte population involved in acute inflammation.
MDSCs	CD11b⁺, CD33⁺, HLA-DR	Myeloid-Derived Suppressor Cells (MDSCs) are critical in tumor immune evasion.

Targeted Application: Antibody-Conjugated Liposomes (Immunoliposomes)

The use of antibody-conjugated liposomes (Immunoliposomes) allows for the precise delivery of therapeutic agents to myeloid cells by targeting the surface markers listed above.

Key applications in myeloid markers:

1. Re-polarization of tumor-associated macrophages (TAMs)

Tumor-associated macrophages often adopt an M2 phenotype that promotes tumor growth. By conjugating liposomes with anti-CD206 or anti-CD163 antibodies, researchers can deliver TLR agonists or small molecules directly into these cells to "re-program" them back into tumor-killing M1 macrophages.

2. Enhanced vaccine delivery via dendritic cells

Targeting CD11c or DEC-205 with immunoliposomes allows for the specific delivery of antigens and adjuvants to dendritic cells. This concentrated delivery ensures efficient antigen processing and presentation, leading to a much stronger and more specific T cell-mediated immune response than systemic administration.

3. Neutralizing myeloid-derived suppressor cells (MDSCs)

MDSCs create an immunosuppressive environment that protects tumors from the immune system. Immunoliposomes targeted via anti-CD33 can deliver cytotoxic agents specifically to MDSCs, depleting these cells and "unlocking" the patient's natural anti-tumor immunity.

4. Anti-inflammatory therapy in chronic disease

In conditions like atherosclerosis or rheumatoid arthritis, overactive monocytes and macrophages drive tissue damage. Liposomes targeted to CD14 or CD11b can deliver potent anti-inflammatory steroids or gene-silencing RNA (siRNA) directly to the site of inflammation, reducing systemic side effects.

The Significance of Marker Monitoring

Understanding myeloid marker expression is critical for both diagnostics and therapeutic design:

Disease progression: Monitoring the shift from CD14⁺⁺ to CD16⁺ monocytes provides insights into systemic inflammatory status.
Prognostic indicators: The density of CD68⁺ macrophage infiltration in tumors often correlates with clinical outcomes.
Target selection: Markers like CD33 serve as the essential "docking stations" for the development of antibody-drug conjugates (ADCs) and targeted nanocarriers.
Validation: Surface markers allow for the precise verification of cell-specific drug uptake during the development of immunoliposomal therapies.

Myeloid cells are the primary orchestrators of both the start and the resolution of immune responses. By pairing lineage-specific markers with the high loading capacity of antibody-conjugated liposomes, Creative Biolabs empowers researchers to transition from broad-spectrum treatments to cell-level precision medicine. We provide "turn-key" custom antibody-liposome conjugation services, validated myeloid antibodies, and functional assay kits to validate your targeted therapies. Just Contact us for more.

For Research Use Only. Not For Clinical Use.